Tekturna Hct
Product Images NDC 70839-112

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tekturna Hct (NDC 70839-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Noden Pharma Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tek01 0005 01)

A line chart showing predicted percentage of patients versus baseline MSSBP (mmHg). The graph includes multiple lines representing different treatment groups: AU200, HCTZ, ALISKIREN, ALISKIREN+HCTZ, and Placebo, illustrating their respective effects across a range of blood pressure values.*

FDA Label Image

Figure 2 (Tek01 0005 02)

A line graph showing predicted percentage of patients versus baseline MSSBP (mmHg) for different treatment groups labeled as AL399, HCTZC, AL399+TCTZ25, and Placebo. The graph displays data within a baseline MSSBP range from 140 to 180 mmHg.*

FDA Label Image

Figure 3 (Tek01 0005 03)

A line graph showing predicted percentage of patients over baseline MSDBP (mmHg) ranging approximately from 90 to 110. The graph compares curves labeled as ALD403, HCTZ25, ALD403+HCTZ25, and Placebo, illustrating their effects on the percentage of patients across different baseline systolic blood pressure values.*

FDA Label Image

Figure 4 (Tek01 0005 04)

A line graph showing the predicted percentage of patients on the vertical axis and baseline MSDBP (mmHg) on the horizontal axis. Curves for All03, HCTZ, All03-HCTZ25, Aliskren, and Placebo are plotted to compare patient responses across different baseline MSDBP values.*

FDA Label Image

Aliskiren Hemifumarate Structural Formula (Tek01 0005 05)

Chemical structure diagram showing the molecular composition of the active ingredient found in Tekturna HCT by Noden Pharma USA, Inc. The structure includes various functional groups and bonds indicating the compound's chemical makeup.*

FDA Label Image

Hydrochlorothiazide Structural Formula (Tek01 0005 06)

Chemical structure of the active ingredient in Tekturna HCT, showing a chlorinated and sulfonylated aromatic ring connected to a bicyclic nitrogen-containing structure with an amide group.*

FDA Label Image

Figure 5 (Tek01 0005 07)

A forest plot illustrating the impact of co-administered drugs on the pharmacokinetics (PK) of aliskiren. The chart shows fold change and 90% confidence intervals for various interacting drugs, including CYP3A4/P-gp inhibitors, antihypertensives, and others, with associated dose adjustment recommendations.*

FDA Label Image

Figure 6 (Tek01 0005 08)

A forest plot displaying the impact of the drug aliskiren on the pharmacokinetics (PK) of various co-administered drugs, including Cmax and AUC changes with 90% confidence intervals. The chart categorizes drugs into antitypertensives and others, showing fold changes relative to the interacting drug alone, along with dosing recommendations, which indicate no dose adjustment for all listed drugs.*

FDA Label Image

Principal Display Panel (Tekturna HCT 150/12.5 mg Label)

Label for Tekturna HCT tablets containing aliskiren and hydrochlorothiazide with a strength of 150 mg/12.5 mg. The label indicates a package size of 30 tablets. It includes the NDC 70839-112-30 and identifies Noden Pharma USA, Inc. as the distributor. The label also features storage instructions and a barcode.*

FDA Label Image

Principal Display Panel (Tekturna HCT 150/25 mg Label)

Label for Tekturna HCT tablets by Noden Pharma USA, Inc. Contains 30 tablets of aliskiren and hydrochlorothiazide. Each tablet strength is 150 mg/25 mg. Includes NDC 70839-125-30 and a barcode. The label also provides storage instructions, manufacturer, and distributor information.*

FDA Label Image

Principal Display Panel (Tekturna HCT 300/12.5 mg Label)

Label for Tekturna HCT tablets containing aliskiren and hydrochlorothiazide, strength 300 mg/12.5 mg. The label indicates a package size of 30 tablets and the product is prescription only. The labeler is Noden Pharma USA, Inc. The label includes storage instructions, barcode, and manufacturer information.*

FDA Label Image

Principal Display Panel (Tekturna HCT 300/25 mg Label)

Label for Tekturna HCT tablets containing 300 mg/25 mg of aliskiren and hydrochlorothiazide. The bottle contains 30 tablets. It is labeled Rx only and manufactured by Noden Pharma USA, Inc. The label includes a barcode and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.